Ginkgo Bioworks Holdings Inc vs Endeavour Silver Corp — how do they compare? Ginkgo Bioworks Holdings Inc trades at $12.93 (market cap $763.64M), while Endeavour Silver Corp trades at $8.66 (market cap $2.54B). The key difference: Endeavour Silver Corp is far larger — about 3.3× Ginkgo Bioworks Holdings Inc's market cap, and Ginkgo Bioworks Holdings Inc is trading nearer its 52-week high, Endeavour Silver Corp nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Ginkgo Bioworks Holdings Inc for 7 Days and Endeavour Silver Corp for 25 Days on average.
| DNA | EXK | |
|---|---|---|
Market Cap | $763.64M | $2.54B |
Volume | 3,204,177 | 7,077,330 |
Sector | Health | Basic Materials |
52-Week High | $15.83 | $14.12 |
52-Week Low | $5.48 | $7.07 |
Typical Hold Time | 7 Days | 25 Days |
Enterprise Value | $865.59M | $2.54B |
Signals from Pluang's Aura AI — not financial advice
Ginkgo Bioworks (DNA) trades at $13.04, up 13.69% in the last session, with a bullish technical signal from moving averages. The company maintains strong gross margins at 68.04% but faces significant losses with a -219.6% net income margin. Recent developments include a $17.5M ARPA-H subcontract for RNA medicine manufacturing and partnerships expanding genetic testing distribution.
While technical momentum appears positive, fundamental challenges persist with substantial cash burn and declining revenue projections. Analyst sentiment is divided equally between buy, hold, and sell ratings. Investment opportunity lies in the company's strategic partnerships and government contracts, balanced against ongoing profitability concerns and competitive pressures in biotech.
Endeavour Silver (EXK) trades at $8.72, up 4.81% today, showing mixed technical signals with bearish moving averages but neutral oscillators. The company demonstrates improving fundamentals with Q1 2026 earnings beating expectations and projected revenue growth from $468M to $737M in 2026. Recent operational developments include Terronera mine resumption and Kolpa expansion, though mechanical issues at Guanacevi mine present near-term challenges.
EXK presents a growth story with strong analyst support (78.57% buy rating) and improving profitability, but faces operational risks and high valuation multiples. The stock's outlook depends on successful mine execution and silver price stability, with technical resistance at $9.00 providing a near-term hurdle for further upside.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →Endeavour Silver is a mid-tier precious metals mining company. It operates silver-gold mines in Mexico and is focused on growing its production and reserves through exploration and the development of new mining projects.
Read more on EXK →